Show Summary Details
Page of

MYCN and Feingold Syndrome 

MYCN and Feingold Syndrome
Chapter:
MYCN and Feingold Syndrome
Author(s):

Hans Van Bokhoven

and Han G. Brunner

DOI:
10.1093/med/9780199934522.003.0034
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 07 March 2021

Feingold syndrome (FS) is a dominantly inherited syndrome with high penetrance and variable clinical expressivity. Its most consistent features are microcephaly, with mental retardation in half of these cases, brachy-mesophalangy, clinodactyly, syndactyly of toes and short palpebral fissures. Gastrointestinal atresias are also frequently observed, mostly manifesting as esophageal atresia/tracheo-esophageal fistula. The MYCN gene on chromosome 2p23-p24 has been identified as the disease-causing gene in this syndrome. Mutations include complete gene deletions, nonsense mutations, frameshift mutations and amino acid substitutions at positions that are crucial for DNA-binding of the protein. All these mutations are predicted to be null-alleles, indicating that haplo-insufficiency is the disease mechanism for FS. Strikingly, MYCN gene amplification and overexpression is found in a number of tumors (e.g. neuroblastomas) and is generally associated with poor prognosis. Such tumors exhibit the opposite cellular phenotype to that observed in FS patients or in N-myc knockout mice. There is convincing evidence indicating that MYCN/N-myc dosage is critically important for cell proliferation and differentiation. Downstream targets of MYCN include the microRNA cluster miR17~92. Interestingly, germline deletions of the microRNA cluster miR17~92 give rise to a phenotype with similarity to Feingold syndrome, suggesting a functional interaction between MYCN and miR17~92 in embryonic development.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.